ESMO: Roche's Tecentriq posts 'unprecedented' benefit in triple-negative breast cancer
admin 20th October 2018 Uncategorised 0Roche’s Tecentriq is gunning to become first in its class of immuno-oncology agents to score an indication in tough-to-treat triple-negative breast cancer, and it’s out with the data that could help it get the job done.
More: ESMO: Roche's Tecentriq posts 'unprecedented' benefit in triple-negative breast cancer
Source: fierce